Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.99 -0.80 (-5.39%)
Streaming Delayed Price Updated: 10:30 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Which stocks are moving on Monday?
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today
Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details
Via Stocktwits
Keep an eye on the top gainers and losers in Monday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Gold Falls 3%; Carter's Shares Gain After Q3 Earnings
 
Via Benzinga
Which stocks are gapping on Monday?
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
Nasdaq Surges 300 Points; Keurig Dr Pepper Shares Jump After Q3 Results
 
Via Benzinga
These stocks are moving in today's pre-market session
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Why Did NTLA Stock Tumble 43% Pre-Market Today?
Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Short Squeeze Frenzy Fuels October's Market Rebound: A Closer Look at Bearish Bets and Bullish Surges
The U.S. stock market has staged a remarkable recovery in October 2025, with major indices reclaiming lost ground amidst a confluence of positive corporate earnings and improving macroeconomic... 
Via MarketMinute
Topics Economy Stocks World Trade
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
Via The Motley Fool
Topics Artificial Intelligence
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
1 Stock Up by 63% This Year That Could Double, According to Wall Street
Some math suggests that even Wall Street is lowballing the stock's potential. 
Via The Motley Fool
What Analysts Are Saying About Intellia Therapeutics Stock
 
Via Benzinga
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought
The growth investor kicked off this week buying up some high-flying stocks. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Topics Artificial Intelligence
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary... 
Via Benzinga
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Tesla To Rally More Than 31%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Expert Outlook: Intellia Therapeutics Through The Eyes Of 5 Analysts
 
Via Benzinga
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff. 
Via Benzinga
Topics ETFs Economy
Intellia Therapeutics Shares Are Ripping Higher: Here's Why
Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones. 
Via Benzinga
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.